Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Cheng-Xu, Ma, Xiao-Ni, Guan, Cong-Hui, Li, Ying-Dong, Mauricio, Dídac, Fu, Song-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107726/
https://www.ncbi.nlm.nih.gov/pubmed/35568946
http://dx.doi.org/10.1186/s12933-022-01516-6
_version_ 1784708546111209472
author Ma, Cheng-Xu
Ma, Xiao-Ni
Guan, Cong-Hui
Li, Ying-Dong
Mauricio, Dídac
Fu, Song-Bo
author_facet Ma, Cheng-Xu
Ma, Xiao-Ni
Guan, Cong-Hui
Li, Ying-Dong
Mauricio, Dídac
Fu, Song-Bo
author_sort Ma, Cheng-Xu
collection PubMed
description Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.
format Online
Article
Text
id pubmed-9107726
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91077262022-05-16 Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management Ma, Cheng-Xu Ma, Xiao-Ni Guan, Cong-Hui Li, Ying-Dong Mauricio, Dídac Fu, Song-Bo Cardiovasc Diabetol Review Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM. BioMed Central 2022-05-14 /pmc/articles/PMC9107726/ /pubmed/35568946 http://dx.doi.org/10.1186/s12933-022-01516-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Ma, Cheng-Xu
Ma, Xiao-Ni
Guan, Cong-Hui
Li, Ying-Dong
Mauricio, Dídac
Fu, Song-Bo
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
title Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
title_full Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
title_fullStr Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
title_full_unstemmed Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
title_short Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
title_sort cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107726/
https://www.ncbi.nlm.nih.gov/pubmed/35568946
http://dx.doi.org/10.1186/s12933-022-01516-6
work_keys_str_mv AT machengxu cardiovasculardiseaseintype2diabetesmellitusprogresstowardpersonalizedmanagement
AT maxiaoni cardiovasculardiseaseintype2diabetesmellitusprogresstowardpersonalizedmanagement
AT guanconghui cardiovasculardiseaseintype2diabetesmellitusprogresstowardpersonalizedmanagement
AT liyingdong cardiovasculardiseaseintype2diabetesmellitusprogresstowardpersonalizedmanagement
AT mauriciodidac cardiovasculardiseaseintype2diabetesmellitusprogresstowardpersonalizedmanagement
AT fusongbo cardiovasculardiseaseintype2diabetesmellitusprogresstowardpersonalizedmanagement

Ejemplares similares